{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:34:15Z","timestamp":1773812055152,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"California Department of Health and Health Care Services","award":["18-95529"],"award-info":[{"award-number":["18-95529"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>With the onset of the COVID-19 crisis, many federal agencies relaxed policies regulating opioid use disorder treatment. The impact of these changes has been minimally documented. The abrupt nature of these shifts provides a naturalistic opportunity to examine adaptations for opioid use disorder treatment in primary care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To examine change in medical and behavioral health appointment frequency, visit type, and management of patients with opioid use disorder in response to COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>A 14-item survey queried primary care practices that were enrolled in a medications for opioid use disorder statewide expansion project. Survey content focused on changes in service delivery because of COVID-19. The survey was open for 18 days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Participants<\/jats:title>\n                <jats:p>We surveyed 338 clinicians from 57 primary care clinics located in California, including federally qualified health centers and look-alikes. A representative from all 57 clinics (100%) and 118 staff (34.8% of all staff clinicians) participated in the survey.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main Measures<\/jats:title>\n                <jats:p>The survey consisted of seven dimensions of practice: medical visits, behavioral health visits, medication management, urine drug screenings, workflow, perceived patient demand, and staff experience.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Results<\/jats:title>\n                <jats:p>A total of 52 of 57 (91.2%) primary care clinics reported practice adaptations in response to COVID-19 regulatory changes. Many clinics indicated that both medical (40.4%) and behavioral health visits (53.8%) were now exclusively virtual. Two-thirds (65.4%) of clinics reported increased duration of buprenorphine prescriptions and reduced urine drug screenings (67.3%). The majority (56.1%) of clinics experienced an increase in patient demand for behavioral health services. Over half (56.2%) of clinics described having an easier or unchanged experience retaining patients in care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Many adaptations in the primary care approach to patients with opioid use disorder may be temporary reactions to COVID-19. Further evaluation of the impact of these adaptations on patient outcomes is needed to determine whether changes should be maintained post-COVID-19.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11606-020-06436-3","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T21:03:21Z","timestamp":1611867801000},"page":"998-1005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics"],"prefix":"10.1007","volume":"36","author":[{"given":"Lauren","family":"Caton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne Chokron","family":"Garneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Briana","family":"Harris-Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-573X","authenticated-orcid":false,"given":"Mark P.","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"issue":"22","key":"6436_CR1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-Assisted Therapies \u2014 Tackling the Opioid-Overdose Epidemic. New England Journal of Medicine. 2014;370(22):2063\u20132066. https:\/\/doi.org\/10.1056\/NEJMp1402780.","journal-title":"New England Journal of Medicine."},{"key":"6436_CR2","doi-asserted-by":"publisher","unstructured":"Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews. 2016;2016(5). https:\/\/doi.org\/10.1002\/14651858.CD011117.pub2.","DOI":"10.1002\/14651858.CD011117.pub2"},{"issue":"2","key":"6436_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/08897077.2019.1572052","volume":"40","author":"M Doernberg","year":"2019","unstructured":"Doernberg M, Krawczyk N, Agus D, Fingerhood M. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis? Substance Abuse. 2019;40(2):148\u2013153. https:\/\/doi.org\/10.1080\/08897077.2019.1572052.","journal-title":"Substance Abuse."},{"key":"6436_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","volume":"78","author":"AS Huhn","year":"2017","unstructured":"Huhn AS, Dunn KE. Why aren\u2019t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment. 2017;78:1\u20137. https:\/\/doi.org\/10.1016\/j.jsat.2017.04.005.","journal-title":"Journal of Substance Abuse Treatment."},{"issue":"2","key":"6436_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1370\/afm.1595","volume":"12","author":"E Hutchinson","year":"2014","unstructured":"Hutchinson E, Catlin M, Andrilla CHA, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Annals of Family Medicine. 2014;12(2):128\u2013133. https:\/\/doi.org\/10.1370\/afm.1595.","journal-title":"Annals of Family Medicine."},{"issue":"1","key":"6436_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMp1803982","volume":"379","author":"JH Samet","year":"2018","unstructured":"Samet JH, Botticelli M, Bharel M. Methadone in primary care - one small step for congress, one giant leap for addiction treatment. New England Journal of Medicine. 2018;379(1):7\u20138. https:\/\/doi.org\/10.1056\/NEJMp1803982.","journal-title":"New England Journal of Medicine."},{"issue":"6","key":"6436_CR7","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","volume":"54","author":"RL Haffajee","year":"2018","unstructured":"Haffajee RL, Bohnert ASB, Lagisetty PA. Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. American Journal of Preventive Medicine. 2018;54(6):S230-S242. https:\/\/doi.org\/10.1016\/j.amepre.2017.12.022.","journal-title":"American Journal of Preventive Medicine."},{"issue":"3","key":"6436_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","volume":"76","author":"K Fiscella","year":"2019","unstructured":"Fiscella K, Wakeman SE, Beletsky L. Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver. JAMA Psychiatry. 2019;76(3):229\u2013230. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3685.","journal-title":"JAMA Psychiatry."},{"key":"6436_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugpo.2019.07.006","volume":"73","author":"CS Davis","year":"2019","unstructured":"Davis CS, Carr DH. Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. International Journal of Drug Policy. 2019;73:42\u201348. https:\/\/doi.org\/10.1016\/j.drugpo.2019.07.006.","journal-title":"International Journal of Drug Policy."},{"key":"6436_CR10","unstructured":"Johns Hopkins Coronavirus Resource Center. COVID-19 United States Cases by County. https:\/\/coronavirus.jhu.edu\/us-map. Accessed 6 Oct 2020."},{"key":"6436_CR11","unstructured":"Johns Hopkins Coronavirus Resource Center. Impact of Opening and Closing Decisions by States. https:\/\/coronavirus.jhu.edu\/data\/state-timeline. Accessed 6 Oct 2020."},{"issue":"1","key":"6436_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12954-020-00370-7","volume":"17","author":"A Dunlop","year":"2020","unstructured":"Dunlop A, Lokuge B, Masters D, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm reduction journal. 2020;17(1):26\u201326. https:\/\/doi.org\/10.1186\/s12954-020-00370-7.","journal-title":"Harm reduction journal."},{"issue":"2","key":"6436_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","volume":"177","author":"AR Williams","year":"2020","unstructured":"Williams AR, Samples H, Crystal S, Olfson M. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder. Am J Psychiatry. 2020;177(2):117\u2013124. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19060612.","journal-title":"Am J Psychiatry"},{"key":"6436_CR14","unstructured":"Drug Enforcement Administration. COVID-19 Information Page. Diversion Control Division. https:\/\/www.deadiversion.usdoj.gov\/coronavirus.html. Accessed 15 Jul 2020."},{"key":"6436_CR15","unstructured":"Department of Justice, United States. Use of Telemedicine While Providing Medication Assisted Treatment (MAT).; 2018."},{"key":"6436_CR16","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid Treatment Program (OTP) Guidance. www.samhsa.gov. Accessed 15 Jul 2020."},{"key":"6436_CR17","unstructured":"Substance Abuse and Mental Health Services Administration. FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergency. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf. Accessed 15 Jul 2020."},{"key":"6436_CR18","unstructured":"U.S. Department of Health & Human Services, Office for Civil Rights. Notification of Enforcement Discretion for Telehealth. Health Information Privacy. Published March 30, 2020. https:\/\/www.hhs.gov\/hipaa\/for-professionals\/special-topics\/emergency-preparedness\/notification-enforcement-discretion-telehealth\/index.html. Accessed 15 Jul 2020."},{"key":"6436_CR19","doi-asserted-by":"publisher","unstructured":"Vecchio S, Ramella R, Drago A, Carraro D, Littlewood R, Somaini L. COVID19 pandemic and people with opioid use disorder: innovation to reduce risk. Psychiatry Research. 2020;289. https:\/\/doi.org\/10.1016\/j.psychres.2020.113047.","DOI":"10.1016\/j.psychres.2020.113047"},{"key":"6436_CR20","doi-asserted-by":"publisher","unstructured":"Marsden J, Darke S, Hall W, et al. Mitigating and learning from the impact of COVID-19 infection on addictive disorders. Addiction. 2020;115(6). https:\/\/doi.org\/10.1111\/add.15080.","DOI":"10.1111\/add.15080"},{"issue":"2","key":"6436_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/08897077.2020.1752351","volume":"41","author":"TC Green","year":"2020","unstructured":"Green TC, Bratberg J, Finnell DS. Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment. Substance Abuse. 2020;41(2):147\u2013149. https:\/\/doi.org\/10.1080\/08897077.2020.1752351.","journal-title":"Substance Abuse."},{"key":"6436_CR22","doi-asserted-by":"publisher","unstructured":"Davis CS, Samuels EA. Opioid Policy Changes During the COVID-19 Pandemic - and Beyond. Journal of addiction medicine. Published online 2020. https:\/\/doi.org\/10.1097\/ADM.0000000000000679.","DOI":"10.1097\/ADM.0000000000000679"},{"issue":"1","key":"6436_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10488-010-0327-7","volume":"38","author":"GA Aarons","year":"2011","unstructured":"Aarons GA, Hurlburt M, Horwitz SM. Advancing a conceptual model of evidence-based practice implementation in public service sectors. Adm Policy Ment Health. 2011;38(1):4\u201323. https:\/\/doi.org\/10.1007\/s10488-010-0327-7.","journal-title":"Adm Policy Ment Health"},{"key":"6436_CR24","unstructured":"McGovern MP, Hurley B, Fisher T, Caton L. Primary Care Practice Adaptations for Patients with Opioid Use Disorder during COVID-19: A Survey."},{"issue":"1","key":"6436_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1146\/annurev-clinpsy-032813-153724","volume":"10","author":"WK Bickel","year":"2014","unstructured":"Bickel WK, Johnson MW, Koffarnus MN, MacKillop J, Murphy JG. The Behavioral Economics of Substance Use Disorders: Reinforcement Pathologies and Their Repair. Annual Review of Clinical Psychology. 2014;10(1):641\u2013677. https:\/\/doi.org\/10.1146\/annurev-clinpsy-032813-153724.","journal-title":"Annual Review of Clinical Psychology."},{"issue":"1","key":"6436_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/02791072.2013.763558","volume":"45","author":"CB Oser","year":"2013","unstructured":"Oser CB, Biebel EP, Pullen E, Harp KL. Causes, Consequences, and Prevention of Burnout among Substance Abuse Treatment Counselors: A Rural versus Urban Comparison. J Psychoactive Drugs. 2013;45(1):17\u201327.","journal-title":"J Psychoactive Drugs"},{"issue":"6","key":"6436_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1370\/afm.1713","volume":"12","author":"T Bodenheimer","year":"2014","unstructured":"Bodenheimer T, Sinsky C. From triple to Quadruple Aim: Care of the patient requires care of the provider. Annals of Family Medicine. 2014;12(6):573\u2013576. https:\/\/doi.org\/10.1370\/afm.1713.","journal-title":"Annals of Family Medicine."},{"issue":"9","key":"6436_CR28","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.mayocp.2018.07.001","volume":"93","author":"YT Yang","year":"2018","unstructured":"Yang YT, Weintraub E, Haffajee RL. Telemedicine\u2019s Role in Addressing the Opioid Epidemic. Mayo Clin Proc. 2018;93(9):1177\u20131180. https:\/\/doi.org\/10.1016\/j.mayocp.2018.07.001.","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"6436_CR29","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","volume":"284","author":"AT McLellan","year":"2000","unstructured":"McLellan AT, Lewis DC, O\u2019Brien CP, Kleber HD. Drug Dependence, a Chronic Medical Illness: Implications for Treatment, Insurance, and Outcomes Evaluation. JAMA. 2000;284(13):1689\u20131695. https:\/\/doi.org\/10.1001\/jama.284.13.1689.","journal-title":"JAMA."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06436-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-020-06436-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06436-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T17:24:04Z","timestamp":1618248244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-020-06436-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["6436"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-06436-3","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]},"assertion":[{"value":"27 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The views expressed in the submitted article are the authors\u2019 own and not an official position of the institutions or funders.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The datasets analyzed during the current study are available from the corresponding author upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}